2021 News

Infex Therapeutics receives MHRA approval to initiate Phase 1 study for RESP-X programme

MHRA grants approval of Phase 1 clinical trial, expected to start in H2 2022 Alderley Park, Cheshire, U.K – Infex Therapeutics, a leader in critical-priority infectious diseases, is pleased to announce it has received approval fr...

Maxwellia appoints Ian Adamson as Strategic Advisor

Maxwellia has appointed Ian Adamson as strategic advisor to shape the next phase of pharmacy medicine launches – a process which involves identifying and converting suitable prescription only medicines into versions people can choose...

Catapult Ventures records 3.3x return from exit of Panthera Biopartners

28 April 2022 - Manchester, UK.  The GM&C Life Sciences Fund, managed by Catapult Ventures, has announced a 3.3x cash return (115.6% IRR), from its exit of Panthera Biopartners Ltd. The exit comes as part of a £10m further fu...

From our portfolio


Digital Healthcare Technology

Rinicare is an intelligent medical device and software company developing and commercialisin...

viewview our portfolio

Our Team

Laurence Vaughan

view complete team

Contact us

Binder House
7 Narborough Wood Park
Desford Road
LE19 4XT

Tel: 0116 238 8200